Patents Examined by Kagnew H. Gebreyesus
  • Patent number: 10316305
    Abstract: The invention relates to a polypeptide having hemicellulase activity. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein and functional equivalents of the gene or the amino acid sequence. The invention also relates to methods for using the polypeptide in industrial processes. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 11, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alrik Pieter Los, Rene Marcel De Jong, Maaike Appeldoorn
  • Patent number: 10316310
    Abstract: The present invention relates to a polypeptide having protease activity comprising a zinc finger protease domain, a helix-turn-helix domain and a GAF domain. The core protein sequence of the protease is shown as SEQ ID NO: 1. The invention also relates to optimized reaction conditions for the protease and methods of increasing the protease activity.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 11, 2019
    Assignee: Zhejiang University
    Inventors: Yuejin Hua, Yunguang Wang, Liangyan Wang
  • Patent number: 10316300
    Abstract: The invention relates to: —a protein having dextran-saccharase activity and the sequence SEQ ID NO: 1 for an amino acid sequence; —a protein having dextran-saccharase activity and the sequence SEQ ID NO: 2 for an amino acid sequence; —a complex containing a substrate and a protein with dextran-saccharase activity —a method for synthesizing dextrans; and —dextrans. The invention also relates to a method for synthesizing gluco-oligosaccharides and gluco-conjugates and to the resulting products.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 11, 2019
    Assignees: INSTITUT NATIONAL DES SCIENCES APPLIQUEES TOULOUSE, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PAUL SABATIER TOULOUSE III
    Inventors: Marlène Vuillemin, Marion Claverie, Claire Moulis, Magali Remaud-Simeon, Pierre Monsan, Etienne Severac, Catherine Fontagne-Faucher
  • Patent number: 10308971
    Abstract: The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: June 4, 2019
    Assignee: Novozymes A/S
    Inventors: Michael Schilling, Christine Lang, Andreas Raab
  • Patent number: 10301373
    Abstract: The present disclosure provides a process for improved production and extraction of recombinant human serum albumin (rHSA) using E. coli as a host system. The process of the instant disclosure provides enhanced recovery of soluble and functional rHSA over conventional known methods.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 28, 2019
    Assignee: Indian Institute of Technology, Delhi
    Inventors: Tapan Kumar Chaudhuri, Ashima Sharma
  • Patent number: 10294504
    Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 21, 2019
    Assignees: La Jolla Pharmaceutical Company, The University of British Columbia
    Inventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
  • Patent number: 10294468
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 21, 2019
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 10287566
    Abstract: Methods of screening for dihydroxy-acid dehydratase (DHAD) variants that display increased DHAD activity are disclosed, along with DHAD variants identified by these methods. Such enzymes can result in increased production of compounds from DHAD requiring biosynthetic pathways. Also disclosed are isolated nucleic acids encoding the DHAD variants, recombinant host cells comprising the isolated nucleic acid molecules, and methods of producing butanol.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: May 14, 2019
    Assignee: Butamax Advanced Biofuels LLC
    Inventors: Kristen J. Kelly, Rick W. Ye
  • Patent number: 10280406
    Abstract: The object of the present invention is to efficiently produce useful terpenoid compounds, and specifically, to provide a method for preparing squalene, which is an important intermediate of terpenoid. The object can be solved by a hydroxymethylglutaryl CoA reductase (HMGR) comprising: (a) an amino acid other than alanine (A) at the 10th position in an S?2 amino acid sequence of HMGR, (b) an amino acid other than proline (P) at the 1st position from the carboxyl terminal in the DKK region of the HMG-CoA binding site of HMGR, (c) an amino acid other than alanine (A) at the 1st position in an L?2 amino acid sequence of HMGR, and (d) an amino acid other than glutamic acid (E) at the 6th position in an L?2 amino acid sequence of HMGR of the present invention.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 7, 2019
    Assignee: ADEKA CORPORATION
    Inventors: Toshihiko Takehana, Seiji Koike, Tomohisa Kuzuyama
  • Patent number: 10273515
    Abstract: The present invention relates to enzyme compositions and processes of producing and using the compositions for the saccharification of lignocellulosic material.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: April 30, 2019
    Assignee: Novozymes A/S
    Inventors: Jeffrey Shasky, Debbie Yaver, Donna Moyer
  • Patent number: 10265415
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 23, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10260053
    Abstract: Compositions are disclosed herein comprising poly alpha-1,3-1,6-glucan with a weight average degree of polymerization (DPw) of at least 1000. This glucan polymer comprises at least 30% alpha-1,3 linkages and at least 30% alpha-1,6 linkages. Further disclosed are glucosyltransferase enzymes that synthesize poly alpha-1,3-1,6-glucan. Ether derivatives of poly alpha-1,3-1,6-glucan and methods of using such derivatives as viscosity modifiers are also disclosed.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 16, 2019
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Jayme L. Paullin, Mark S. Payne, T. Joseph Dennes, Yefim Brun, Rakesh Nambiar, Thomas H Scholz
  • Patent number: 10246495
    Abstract: The present invention relates to polypeptides which are Gal2 variants comprising at least one amino acid substitution at a position corresponding to T354, and optionally further amino acid substitution(s). The present invention further relates to nucleic acid molecules encoding the polypeptides and to host cells containing said nucleic acid molecules. The present invention further relates to a method for the production of bioethanol and/or other bio-based compounds, comprising the expression of said nucleic acid molecules, preferably in said host cells. The present invention also relates to the use of the polypeptides, nucleic acids molecule or host cells for the production of bioethanol and/or other bio-based compounds, and/or for the recombinant fermentation of biomaterial containing pentose(s), preferably D-xylose and/or L-arabinose.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: April 2, 2019
    Assignee: BUTALCO GMBH
    Inventors: Eckhard Boles, Heiko Dietz, Alexander Farwick, Virginia Schadeweg, Mislav Oreb
  • Patent number: 10240169
    Abstract: Described are recombinant microorganisms characterized by having phosphoketolase activity, having a diminished or inactivated Embden-Meyerhof-Parnas pathway (EMPP) by inactivation of the gene(s) encoding phosphofructokinase or by reducing phosphofructokinase activity as compared to a non-modified microorganism and having a diminished or inactivated oxidative branch of the pentose phosphate pathway (PPP) by inactivation of the gene(s) encoding glucose-6-phosphate dehydrogenase or by reducing glucose-6-phosphate dehydrogenase activity as compared to a non-modified microorganism. These microorganisms can be used for the production of useful metabolites such as acetone, isobutene or propene.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: March 26, 2019
    Assignee: Scientist of Fortune, S.A.
    Inventor: Philippe Marliere
  • Patent number: 10240158
    Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: March 26, 2019
    Assignee: Yale University
    Inventors: Dieter Soll, Caroline Aldag, Michael Hohn, Corwin Miller
  • Patent number: 10233474
    Abstract: This document describes materials and methods for, for example, producing 6-hydroxyhexanoic acid using a ?-ketothiolase or synthase and an alcohol O-acetyltransferase to form a 6-acetyloxy-3-oxohexanoyl-CoA intermediate. This document describes biochemical pathways for producing 6-hydroxyhexanoic acid using a ?-ketothiolase or synthase and an alcohol O-acetyltransferase to form a 6-acetyloxy-3-oxohexanoyl-CoA intermediate. 6-hydroxyhexanoic acid can be enzymatically converted to adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine or 1,6-hexanediol. This document also describes recombinant hosts producing 6-hydroxyhexanoic acid as well as adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine and 1,6-hexanediol.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 19, 2019
    Assignee: INVISTA North America S.á.r.l.
    Inventors: Alexander Brett Foster, Mariusz Kamionka, Nadia Fatma Kadi, Adriana Leonora Botes, Alex Van Eck Conradie
  • Patent number: 10227643
    Abstract: The present invention provides DNA polymerases and their use in various applications. The present invention also relates to uses and methods utilizing the DNA polymerase of the present invention for discriminating between matched and mismatched primers or detecting SNP or methylated cytosine. The present invention also relates to kits comprising such DNA polymerases.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 12, 2019
    Assignee: UNIVERSITAET KONSTANZ
    Inventors: Andreas Marx, Matthias Drum, Ramon Kranaster
  • Patent number: 10221410
    Abstract: Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are DNA for coding the improved nitrile hydratase, a recombinant vector that contains the DNA, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase. Also provided is a method for producing an amide compound that uses the culture or a processed product of the culture. The improved nitrile hydratase contains an amino acid sequence represented by SEQ ID NO: 50 (GX1X2X3X4DX5X6R) in a beta subunit, and is characterized in that X4 is an amino acid selected from a group comprising cysteine, aspartic acid, glutamic acid, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, serine and threonine.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: March 5, 2019
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Fumiaki Watanabe, Ai Hara, Takanori Ambo, Aya Kitahara
  • Patent number: 10220080
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 5, 2019
    Assignees: aTyr Pharam, Inc., Pangu Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, Zhiwen Xu, John D. Mendlein
  • Patent number: 10215701
    Abstract: A method of monitoring water-soluble treatment chemicals in a fluid that is immiscible with water and which may or may not contain some aqueous fluid, the method using at least one reagent that produces an optically detectable product, the detection step can take place without separation of the aqueous phase containing the treatment chemicals from the fluid immiscible with water.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 26, 2019
    Assignee: Lux Assure Limited
    Inventors: Fiona MacKay, Emma Perfect, Catherine Rowley-Williams, Anne-Marie Fuller